Former Indevus VP Agrees To Insider Trading Deal

Law360, New York (January 11, 2010, 6:05 PM EST) -- A former vice president of Indevus Pharmaceuticals Inc. has agreed to pay the U.S. Securities and Exchange Commission over $130,000 to settle insider trading allegations brought by regulators that accused the executive of dumping stock after he learned that approval of one of the biotechnology company's drugs was to be delayed.

Brooke Wagner, the former vice president of communications at Indevus, which was acquired by Endo Pharmaceuticals Inc. last year, neither admitted nor denied the allegations of the complaint in a consent judgment submitted by the...
To view the full article, register now.